Clinical trials: Crohn's
Crohn's Disease
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
Adults with Crohn's disease that is clinically active despite conventional treatment will be eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental drug) or placebo (inactive drug).
- Trial name
- OPERA (NCT01276509)
- Testing
- PF-00547659 SC injection
- Where
- 137 sites in United States, Austria and 14 more
- Volunteers
- 265 people
- Sponsor
- Shire
Crohn Disease, Ulcerative Colitis
The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States
A multi-center observational study based at referral centers and community hospitals within the US. Patients' blood will be collected at enrollment for testing with PredictSURE IBD™, which will occur at a later date.
- Conditions
- Crohn Disease, Ulcerative Colitis, IBD, Inflammatory Bowel Diseases
- Trial name
- NCT03952364
- Testing
- PredictSURE IBD™
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- PredictImmune Ltd
Perianal Fistula, Primary; Complex
Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)
This is an open follow-up clinical trial to evaluate a sustained efficacy and safety of ANTG-ASC injection for 4 months (6 months after final dose injection) after Phase II clinical trial.
- Trial name
- ANTG (NCT01623453)
- Testing
- Autologous adipose derived stem cells(low dose group), Autologous adipose derived stem cells(high dose group)
- Where
- 2 sites in South Korea
- Volunteers
- 6 people
- Sponsor
- Anterogen Co., Ltd.
Crohn's Disease
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.
- Trial name
- NCT02425111
- Testing
- Vedolizumab
- Where
- 79 sites in United States, Belgium and 6 more
- Volunteers
- 101 people
- Sponsor
- Takeda
Crohn
Study of Allogenic Adipose-derived Stem Cells in Crohn's Fistula
Adipose-derived stem cells have properties of differentiation to various types of cells, immunomodulatory effects. adipose-derived stem cells (ASCs) show also low immunogenicity.
- Trial name
- ALLO-ASC (NCT01440699)
- Testing
- Allogenic human adipose-derived stem cells
- Where
- 3 sites in South Korea
- Volunteers
- 6 people
- Sponsor
- Anterogen Co., Ltd.
Complex Perianal Fistula
Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula
Mesenchymal stem cells derived from adipose tissue are pluripotent to differentiate into myocytes, adipocytes or others. They have an immunosuppressive activity. Complex perianal fistula is difficult to cure and easy to relapse.
- Trial name
- ANTG-ASC-210 (NCT01314092)
- Testing
- Autologous cultured adipose derived stem cells(low dose group), Autologous cultured adipose derived stem cells(high dose group)
- Where
- 6 sites in South Korea
- Volunteers
- 15 people
- Sponsor
- Anterogen Co., Ltd.
Crohn's Disease
Vagus Nerve Stimulation in Crohn's Disease
This is an open label interventional study using an implantable vagus nerve stimulation device in patients with Crohn's disease who have active disease despite treatment with a tumor necrosis factor (TNF) antagonist drug.
- Trial name
- NCT02311660
- Testing
- Vagus Nerve Stimulation Device
- Where
- 4 sites in Croatia, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- SetPoint Medical Corporation
Ulcerative Colitis, Crohn's Disease
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to…
- Trial name
- NCT00619489
- Testing
- vedolizumab
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Crohn Disease
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
The purpose of this study is to evaluate the effectiveness and safety of anti-TNF chimeric monoclonal antibody (cA2) compared to placebo in the treatment of patients with fistulizing Crohn's disease.
- Trial name
- NCT00269841
- Testing
- Infliximab 10 mg/kg, Infliximab 5 mg/kg
- Volunteers
- 94 people
- Sponsor
- Centocor, Inc.
Crohn's Disease
Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease
A double-blind, multicentre, stratified by centre, randomised, parallel study with two groups of adult patients operated on for Crohn's disease, to determine if oral ingestion of probiotics could prevent the appearance of Crohn's…
- Trial name
- NCT01698970
- Testing
- 1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test), 2- excipients (150 mg) in capsule (control)
- Where
- France
- Volunteers
- 122 people
- Sponsor
- Danone Global Research & Innovation Center
Crohn's Disease
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease…
- Trial name
- NCT01258205
- Testing
- AMG 139
- Where
- 7 sites in United States, Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Crohn Disease
A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials
The main objectives of this study are to evaluate the long-term safety of spesolimab in patients with perianal fistulising Crohn's disease who have completed treatment in parent trials and to evaluate the long-term efficacy of…
- Trial name
- NCT04362254
- Testing
- Spesolimab
- Where
- 7 sites in Austria, Belgium and 3 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Crohn Disease
An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease
The purpose of this program is to provide early access to ustekinumab where it is commercially unavailable for the treatment of participants with moderately to severely active Crohn's disease who have failed treatment with…
- Trial name
- NCT03362736
- Testing
- Ustekinumab
- Where
- 6 sites in Brazil
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
A Study of Vedolizumab in Adults With Crohn's Disease (CD)
The main aim of this study is to see if adults with CD treated with vedolizumab have less symptoms and inflammation of the bowel assessed by ultrasonography.
- Trial name
- SUNRISE (NCT05192863)
- Testing
- No Intervention
- Where
- 10 sites in Canada, Israel and 1 more
- Volunteers
- 72 people
- Sponsor
- Takeda
Crohn's Disease
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive…
- Trial name
- DIVERSITY1 (NCT02914561)
- Testing
- Filgotinib
- Where
- 513 sites in United States, Argentina and 39 more
- Volunteers
- 1,372 people
- Sponsor
- Lakefront Biotherapeutics NV
Crohn Disease
Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
The purpose of study is to test the effects of an experimental medication GED-0301 (mongersen) in patients who have active Crohn's disease. The study will test GED-0301 compared to placebo for 52 weeks.
- Trial name
- NCT02596893
- Testing
- GED-0301
- Where
- 538 sites in United States, Australia and 33 more
- Volunteers
- 701 people
- Sponsor
- Celgene
Crohn's Disease
Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks.
- Trial name
- CD05 (NCT00740103)
- Testing
- Semapimod
- Where
- 26 sites in United States, Belgium and 3 more
- Volunteers
- 119 people
- Sponsor
- Ferring Pharmaceuticals
Crohn's Disease
Treatment With Infliximab in a Medical Setting (Study P05587)
This is an open-label, interventional study where a subset of participants will be randomized to one of two treatment-optimization strategies.
- Trial name
- OPTIMIST (NCT00752622)
- Testing
- Infliximab 5 mg/kg, Infliximab 5 mg/kg every 6 weeks, Infliximab 7 mg/kg every 8 weeks
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Crohn Disease
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease
The purpose of this study is to evaluate the effectiveness and safety of anti-TNF chimeric monoclonal antibody (cA2) compared to placebo in patients with active Crohn's disease.
- Trial name
- NCT00269854
- Testing
- Infliximab 5 mg/kg, Infliximab 10 mg/kg, Infliximab 20 mg/kg
- Volunteers
- 108 people
- Sponsor
- Centocor, Inc.